KEEP BUT DO NOT DISPLAY

Federal health authorities last week reported the stunning drop in the obesity rate among 2- to 5-year-old children, the first broad decline in the epidemic. The decrease emerged from a major federal health survey that experts say is the gold standard for evidence on what Americans weigh. The trend came …

Surescripts Finds Some Data May Be Inaccurate Surescripts is reporting a potential inaccuracy of electronically transmitted medication history information used for medication reconciliation. See this PDF report for more details.  

A new study which tracked a sample of more than 7,700 children through grade school across the U.S. found that of children between ages 5 and 14, nearly 12% developed obesity — 10% of girls and nearly 14% of boys. The study found that much of a child’s "weight fate” …

Researchers found that short-term overeating and reduced physical activity lowered participants’ insulin sensitivity and altered expression patterns of several genes and proteins within adipose tissue. The study included 26 healthy, habitually active men aged 18 to 32 years. The affected genes are involved in nutritional homeostasis, metabolism, and insulin action …

Michael Wirth, MSPH, Ph.D., of the University of South Carolina, Columbia, analyzed the relationship between shiftwork and pro-inflammatory diet using data from a nationwide sample of employed adults. Based on diet questionnaires, the researchers calculated a "dietary inflammatory index" (DII) for each individual. The greater the DII score, the more …

FDA to Review Saxagliptin for Possible Heart Failure Risk More to come in next week’s issue.

Cyanidin and delphinidin, when encapsulated in nanoliposoms, decrease in vitro glycation of albumin and hemoglobin A. They also decrease blood glucose and blood cholesterol in diabetic mice. Iranian researchers investigated the effects of these materials in two forms of free and nanoliposomal on decreasing the damages caused by diabetes. Planta …

Oramed has submitted a protocol to the FDA to initiate a Phase 2a trial of its orally ingestible insulin capsule, ORMD 0801, for type 1 diabetes. The double-blind, randomized, placebo controlled, seven-day study design will be carried out at an inpatient setting on twenty-four type 1 diabetic patients. It’s hope …

America’s biopharmaceutical research companies currently are developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development — all either in clinical trials or under review by the FDA — include 30 for type 1 diabetes, 100 for type 2 and 52 …

FDA Approves Continuous Glucose Monitor for Children  The FDA has expanded the approval of the Dexcom G4 Platinum continuous glucose monitoring (CGM) system to include use for children aged 2 to 17 years of age despite reduced accuracy compared with adults.